AHA 2020 | AFFIRM-AHF: Ferric Carboxymaltose and Fewer Hospitalizations for Cardiac Failure

Correcting iron deficiency in patients with cardiac failure might reduce the risk of new hospitalizations according to the AFFIRM-AHF published in the Lancet and presented at AHA 2020.

The combined primary end point of death and hospitalizations was not met; yet the study showed a significant reduction of 26% in hospitalization rate.

Irrespective of the presence of anemia, iron deficiency is among the predictors of bad prognosis and is present in over 70% of patients with cardiac failure.

This new study data support the administration of intravenous ferric carboxymaltose for patients with iron deficiency (with or without anemia) and less than 50% ejection fraction. Therefore, rather than a bad prognosis factor, iron deficiency has become a changeable factor. 

AFFIRM-AHF was a multicenter study including 1108 patients hospitalized for cardiac failure. They all had iron deficiency defined as ferritin <100 μg/L, or 100–299 μg/L with transferrin saturation <20%). Mean age was 71 and mean ejection fraction was 33%. Before discharge, patients were randomized to endovenous iron vs. placebo. 


Read also: AHA 2020 | Statins: Confirmed Benefits for the Elderly.


At 52 weeks followup, cardiovascular events rate resulted similar between the branches, as was the combined end point of death and hospitalization. However, when looked at separately, new hospitalization rate saw a significant reduction of 26%.

hierro-en-ICC

Original Title: Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.

Reference: Ponikowski P et al. Lancet. 2020; Epub ahead of print y presentado en las sesiones científicas del AHA 2020.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which reflects in lower rates of target lesion...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral anticoagulant (OAC) therapy. This creates a complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...